Tetrahydrobiopterin: a critical cofactor for eNOS and a strategy in the treatment of endothelial dysfunction?
Tiefenbacher
C P
CP
D000818:Animals; D001120:Arginine / Q000008:administration & dosage; D001708:Biopterins / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism*; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology; D002986:Clinical Trials as Topic; D003331:Coronary Vessels / Q000187:drug effects / Q000378:metabolism; D004285:Dogs; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism* / Q000503:physiopathology; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D006632:Histamine / Q000494:pharmacology; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy / Q000378:metabolism; D066298:In Vitro Techniques; D007261:Infusions, Intra-Arterial; D007476:Ionophores / Q000494:pharmacology; D009569:Nitric Oxide / Q000378:metabolism; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors / Q000378:metabolism*; D052250:Nitric Oxide Synthase Type III; D011621:Pteridines / Q000378:metabolism / Q000627:therapeutic use; D011622:Pterins; D017382:Reactive Oxygen Species / Q000378:metabolism; D013045:Species Specificity; D013373:Substance P / Q000494:pharmacology; D013552:Swine; D014662:Vasoconstrictor Agents / Q000008:administration & dosage; D014665:Vasodilator Agents / Q000627:therapeutic use; D019323:omega-N-Methylarginine / Q000008:administration & dosage
D004791:Enzyme Inhibitors; D007476:Ionophores; D011621:Pteridines; D011622:Pterins; D017382:Reactive Oxygen Species; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D001708:Biopterins; D019323:omega-N-Methylarginine; D009569:Nitric Oxide; D013373:Substance P; D006632:Histamine; D001120:Arginine; C016727:sepiapterin; C496314:NOS3 protein, human; D019001:Nitric Oxide Synthase; D052250:Nitric Oxide Synthase Type III; C003402:sapropterin